support@mellalta.com   +1 (304) 470-2225
Menu
0

How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?

Biotech & Pharma, Clinical Trials by Mellalta Analyst Leave a Comment on How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?
SELINEXOR-XPOVIO-COMPETITIVE-POSITIONING-IN-DLBCL

Karyopharm’s Selinexor (Xpovio)  an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large […]

Read More

Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events

Biotech & Pharma, Clinical Trials, Gene Therapy by Mellalta Analyst Leave a Comment on Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events
Liso-cel Strategy

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]

Read More

Get In Touch

Let's keep the conversation going

Contact Us